Detection of c-erbB-2/neu and fibroblast growth factor-3/INT-2 but not epidermal growth factor receptor gene amplification in endometrial cancer by differential polymerase chain reaction.
BACKGROUND
It currently is well established that the activation of protooncogenes could trigger uncontrolled cell growth and cancer development. Although this correlation already has been evidenced in several human tumors, no conclusive studies have related oncogene activation with the development of endometrial neoplasia. Nevertheless, few reports suggest that c-erbB-2/neu, which is a prognostic marker in breast cancer, epidermal growth factor receptor (EGFR), which is overexpressed in a variety of neoplasms, and fibroblast growth factor-3 (FGF-3/INT-2), which has been found to be amplified in breast and ovarian cancer, could be implicated in the development of endometrial adenocarcinoma.


METHODS
Amplification of c-erbB-2/neu, EGFR, and FGF-3/INT-2 was examined in 50 endometrial carcinomas, 10 adenomatous hyperplasias, and 50 normal endometrial samples, using the genomic differential polymerase chain reaction with the single copy reference gene interferon-gamma. Quantitation of the ratios between the amplified bands was assessed by image analysis.


RESULTS
c-erbB-2 and FGF-3/INT-2 were amplified in a first group of 7 (14%) and a further group of 7 (14%) patients, respectively, of a total of 50 in whom endometrial cancer had been studied. In the latter seven, a strong correlation between this genetic marker and an advanced disease stage (International Federation of Gynecology and Obstetrics Stage III) was found. In two patients, both genes were amplified. No EGFR gene amplification was detected in any case.


CONCLUSIONS
c-erbB-2/neu but not EGFR gene amplification was detected and FGF-3/INT-2 amplification and advanced disease were correlated in endometrial cancer.
Esteller
M
M
Unitat de Recerca Biomèdica, Hospital Universitari Materno-Infantil Vall d'Hebrón, Barcelona, Spain.
García
A
A
Martínez i Palones
J M
JM
Cabero
A
A
Reventós
J
J
D000230:Adenocarcinoma / Q000235:genetics* / Q000473:pathology; D000368:Aged; D000369:Aged, 80 and over; D001483:Base Sequence; D014408:Biomarkers, Tumor / Q000235:genetics*; D004273:DNA, Neoplasm / Q000032:analysis; D004714:Endometrial Hyperplasia / Q000235:genetics* / Q000473:pathology; D016889:Endometrial Neoplasms / Q000235:genetics* / Q000473:pathology; D066246:ErbB Receptors / Q000235:genetics*; D005260:Female; D051518:Fibroblast Growth Factor 3; D005346:Fibroblast Growth Factors / Q000235:genetics*; D015870:Gene Expression; D018734:Genes, erbB-2; D006801:Humans; D008875:Middle Aged; D008969:Molecular Sequence Data; D009367:Neoplasm Staging; D016133:Polymerase Chain Reaction / Q000379:methods; D011518:Proto-Oncogene Proteins / Q000235:genetics*
D014408:Biomarkers, Tumor; D004273:DNA, Neoplasm; C496444:FGF3 protein, human; D051518:Fibroblast Growth Factor 3; D011518:Proto-Oncogene Proteins; D005346:Fibroblast Growth Factors; D066246:ErbB Receptors